A patient came into my office a few months ago, opened a folder on her phone, and showed me a long list of skincare products she had been cycling through for the past two years. Retinol. Vitamin C. Bakuchiol. Three different growth factor serums. A peptide moisturizer. A red light mask. She was 46. She told me she felt like she was "throwing money at her face" without understanding any of it. She had just heard about copper peptides on a podcast and wanted to know if it was the next thing to try or the next thing to ignore. Here is what I actually think about GHK-Cu in perimenopause: where the data is strongest, where it is weaker, and how I think about it in my own practice.

If you are a woman in your 40s who has spent decades being the one who holds it all together — the high performer, the fixer, the person everyone leans on — you may have noticed something lately that you can't quite name. The same stressors you used to absorb without a second thought now leave you wired, depleted, and staring at the ceiling at 3 a.m. You are doing everything you used to do, but the buffer that made it feel effortless seems to have quietly disappeared. You are not imagining it, and you are not failing.

Oxytocin is a nine–amino-acid peptide hormone produced in the hypothalamus and released by the posterior pituitary gland. Most of us learned about it in two contexts: labor and breastfeeding. Synthetic oxytocin (Pitocin) has been used clinically for more than fifty years to induce contractions and support milk letdown. What we didn't learn in medical school is that oxytocin receptors are found throughout the body — in the brain, the cardiovascular system, the gut, the bones, the skin, and the vaginal epithelium. This receptor distribution is the reason oxytocin has been investigated for an unusually wide range of conditions: chronic pain, social anxiety, postpartum depression, autism spectrum traits, gastroparesis, weight regulation, and — most relevant to us — sexual function and vaginal tissue health in women.

A patient came into my office recently — 43 years old, regular cycles since adolescence, diagnosed with PMDD in her late twenties. She had spent more than a decade managing it well: an SSRI during the luteal phase, consistent sleep, regular exercise, a diet that worked for her. She knew her pattern. But in the past year, that pattern had changed. This presentation is common in my practice, and the reason for it is something most clinicians were never taught: the relationship between estrogen and histamine, and what happens to that relationship during perimenopause.

If you've spent any time on social media in the past year, you've seen the wave: women in their 40s describing the same cluster of symptoms — losing words mid-sentence, missing deadlines for the first time in their lives, drowning in browser tabs and unfinished tasks — and asking the same question: Is this ADHD, or is this perimenopause? As a menopause-trained physician, here's how I think about it, drawing on traditional medicine, lifestyle medicine, and functional medicine.

By the time many women notice their first hot flash or skipped period, their bones have already started a quiet countdown. In the years surrounding menopause, women can lose up to 10% of their bone mass — and the steepest decline begins in perimenopause, often before any "official" diagnosis of menopause is made. The good news? This is also when intervention works best. Bone is living tissue. It responds — sometimes dramatically — to mechanical loading, hormonal signaling, and the right micronutrients. This guide covers the four pillars of perimenopausal bone protection: strategic exercise, whole-body vibration, early estradiol therapy, and targeted nutrient support (vitamin D3 with K2) — all backed by peer-reviewed evidence.

Many women entering perimenopause are told by their clinicians that a single follicle-stimulating hormone (FSH) blood test will determine whether they are in the menopausal transition and whether they are candidates for menopause hormone therapy (MHT). This practice is widespread, but it is not supported by current evidence or by leading menopause guidelines. Understanding why requires a clear look at what FSH is, how it behaves during perimenopause, and what measures actually correlate with both menopausal status and the likelihood of benefit from treatment.

If you’ve noticed your sleep getting worse, your anxiety creeping up, or your body taking longer to bounce back from a workout, you’re not imagining things. Something real is shifting inside your body during perimenopause — and there’s a simple, trackable number that can help you see it happening: Heart Rate Variability, or HRV. HRV isn’t just for fitness enthusiasts with fancy watches. It’s a powerful window into how well your nervous system is coping with everything life (and hormones) are throwing at it. And the best part? You can track it from your wrist and take real steps to improve it.

Osteoporosis is often called “the silent thief” because it steals bone density without warning — no pain, no symptoms, and no red flags — until a fracture occurs. Despite affecting over 200 million people worldwide and causing more than 8.9 million fractures annually, our screening guidelines remain reactive rather than proactive, particularly for women under 65 who carry significant risk factors. As clinicians, we must ask ourselves: are we waiting too long to look?

Yesterday, a patient in her early forties sat across from me describing something she had never experienced before: her heart would suddenly race for no apparent reason, jolting her awake at 2 a.m. She could not fall back asleep. She felt foggy at work. She wondered if something was seriously wrong. Nothing was wrong with her heart. What she was experiencing were some of the earliest signals of perimenopause. The purpose of this blog is to walk you through the major body systems affected by perimenopause and to show you what to expect at each phase. My hope is that by understanding these changes, you will feel empowered rather than frightened, and that you will recognize the signals your body is sending you as it moves through this natural, but sometimes disorienting, transition.

If you’re a woman in your late thirties or forties experiencing mood swings, brain fog, weight gain, insomnia, crushing fatigue, or a vanishing libido, you’ve probably been told one of two things: “It’s just stress,” or “You’re too young for menopause.” As a clinician who works with women navigating the perimenopause transition every day, I want to be clear: that advice is outdated, and it is leaving millions of women suffering unnecessarily. The research is catching up to what many of us are seeing in practice—and what women have been telling us about their own bodies for years.

If you've been told your labs are "normal" while experiencing brain fog, night sweats, crippling anxiety, or sleep disturbances, you're not imagining things. You are not crazy. And you're certainly not alone. At Bonza Health, we hear this story constantly: women in their late 30s, 40s, and early 50s who know something has changed in their bodies seek help from their healthcare providers, only to be told that because their FSH isn't elevated or their estradiol looks "fine," they don't need hormone therapy. They're sent home with suggestions to reduce stress, exercise more, or consider an antidepressant.

If you're waking up multiple times a night drenched in sweat, unable to fall back asleep, and feeling exhausted all day, you're not alone. For many women going through menopause, severe sleep disruption is more debilitating than hot flashes. Yet the conversation around menopausal hormone therapy often oversimplifies the solution. The truth is, not all hormone therapy is created equal. The type of hormones you use, how they're delivered, and when you start them can mean the difference between relief and continued suffering, or even between safety and risk.

Breast cancer survival rates continue to improve, with over 4 million survivors in the United States alone. However, the journey beyond diagnosis presents significant challenges to quality of life, particularly for women with hormone receptor-positive (HR+) cancers who require long-term endocrine therapy. Sexual dysfunction affects up to 93% of women on aromatase inhibitor therapy, profoundly impacting intimate relationships and marital satisfaction. This article examines the biological mechanisms underlying these challenges, the impact on relationships and marriages, and evidence-based treatment strategies specifically tailored for HR+ breast cancer survivors seeking to reclaim their sexual health and intimate connections.

As a physician, I've dedicated my career to bridging two worlds of medical knowledge—I'm trained by both the Institute for Functional Medicine (IFM) and the Menopause Society. This dual perspective lets me offer a blended, cost-effective approach that prioritizes both your safety and your long-term vitality. My goal is simple: help you feel and function better by addressing the root causes of your symptoms while using clinically proven treatments.

The relationship between estradiol (the primary form of estrogen in the female body) and cholesterol metabolism is well-established in the medical literature, yet it remains one of the most overlooked factors in women's cardiovascular health. Research published in peer-reviewed journals consistently demonstrates that declining estrogen levels fundamentally alter how the body processes cholesterol. Understanding this connection can empower you to have more informed conversations with your healthcare provider and advocate for your cardiovascular health.

Peptides, while recommended in some situations, are not a replacement for foundational health. They are not a shortcut, not a magic solution, and certainly not appropriate for everyone. In my practice, I only consider peptides as a potential addition after we've optimized hormonal health, addressed nutritional deficiencies, regulated nervous system strain, and established consistent lifestyle habits including strength training, quality sleep, and stress reduction.

On November 10, 2025, the FDA announced the removal of black box warnings from menopausal hormone therapy products—a decision that FDA Commissioner Dr. Marty Makary called "one of the greatest mistakes in modern medicine" to finally correct[1]. As a physician who specializes in perimenopause and menopause care in Ohio, I've spent years watching qualified women be denied treatment because of outdated fears. This announcement should be cause for celebration. And it is, but with important caveats that every woman and clinician needs to understand.

Perimenopause can be a significant transition in a woman’s life—one that is widely misunderstood and often neglected in conventional healthcare. If you’re experiencing shifts in mood, energy, cognition, or bodily comfort in your 30s, 40s, or early 50s, you are not alone. This comprehensive guide will empower you to understand perimenopause, recognize its earliest and most surprising signs, and know when to seek help. At Bonza Health, our holistic approach centers your unique experience—because perimenopause is not “one size fits all.”

A groundbreaking 2025 randomized controlled trial, recently published in the Journal of the American Nutrition Association, looked specifically at the effects of creatine on brain metabolism, mood, reaction time, and lipid health in midlife women. The results were remarkable: even low doses of creatine hydrochloride led to measurable improvements in brain energy, focus, and emotional balance—with no identified adverse effects.